Evidence map›Paper›PMID 26973599›Full record

ReviewFrontiers in endocrinology2016

Cancer Stem Cells in the Thyroid.

Yuji Nagayama, Mika Shimamura, Norisato Mitsutake

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Changing Face ofFrontiers in surgery · 2020
    Pooled it
  2. Article
  3. Review
  4. Carcinogenesis trajectories.Frontiers in cell and developmental biology · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Sex Bias in Differentiated Thyroid Cancer.International journal of molecular sciences · 2021
    Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Functions of stem cells of thyroid glands in health and disease.Reviews in endocrine & metabolic disorders · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuji NagayamaDepartment of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University , Nagasaki , Japan.
Mika ShimamuraDepartment of Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University , Nagasaki , Japan.
Norisato MitsutakeDepartment of Radiation Medical Sciences, Atomic Bomb Disease Institute, Nagasaki University , Nagasaki , Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cancer stem cell (CSC) model posits that CSCs are a small, biologically distinct subpopulation of cancer cells in each tumor that have self-renewal and multi-lineage potential, and are critical for cancer initiation, metastasis, recurrence, and therapy-resistance. Numerous studies have linked CSCs to thyroid biology, but the candidate markers and signal transduction pathways that drive thyroid CSC growth are controversial, the origin(s) of thyroid CSCs remain elusive, and it is unclear whether thyroid CSC biology is consistent with the original hierarchical CSC model or the more recent dynamic CSC model. Here, we critically review the thyroid CSC literature with an emphasis on research that confirmed the presence of thyroid CSCs by in vitro sphere formation or in vivo tumor formation assays with dispersed cells from thyroid cancer tissues or bona fide thyroid cancer cell lines. Future perspectives of thyroid CSC research are also discussed.

Indexed as

aldehyde dehydrogenasecancer stem cellsepithelial–mesenchymal transitionthyroid cancerthyrosphere

Identifiers

PMID26973599
PMCPMC4770029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.